Editas Medicine, Inc. (NASDAQ:EDIT) Q2 2023 Earnings Call Transcript
Operator: Good morning and welcome to Editas Medicine's Second Quarter Conference Call. There will be a question-and-answer session at the end of this call.
Editas Medicine Inc. (EDIT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 3,453,744 | $28,424,313 | 1.31% | |
| 2. | Avidity Partners Management David Witzke And Michael Gregory | 3,000,000 | $24,690,000 | 0.86% | |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,838,317 | $23,359,347 | 0.04% | |
| 4. | Woodline Partners Michael Rockefeller And Karl Kroeker | 2,749,305 | $22,626,780 | +4% | 0.26% |
| 5. | Millennium Management Israel Englander | 1,369,822 | $11,273,635 | +7% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $45.51 | 5,800 | Director | 22,700 | 2021-03-03 | Filing | |
| $46.27 | 25,000 | Officer, Director | 35,000 | 2021-03-02 | Filing | |
| $23.94 | 10,200 | Director | 16,900 | 2019-03-05 | Filing | |
| $38.03 | 10,000 | Director | 10,000 | 2018-05-18 | Filing | |
| $37.28 | 6,700 | Director | 6,700 | 2018-05-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.82 | 103 | Officer | 75,728 | 2023-09-06 | Filing | |
| $8.59 | 702 | 75,831 | 2023-08-11 | Filing | ||
| $8.39 | 141 | 76,533 | 2023-08-08 | Filing | ||
| $8.80 | 4,317 | 72,055 | 2023-07-19 | Filing | ||
| $9.50 | 6,486 | 130,169 | 2023-06-05 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 8,165,474 | $67,201,851 | 0% | |
| 2. | 7,595,696 | $62,512,576 | 0% | |
| 3. | 6,641,679 | $54,661,018 | 0% | |
| 4. | 1,767,229 | $14,544,015 | 0% | |
| 5. | 1,704,958 | $14,031,803 | 0% |
News See All
10 DNA Stocks Billionaires Are Loading Up On
Genomics is the study of a complete set of DNA within an organism.
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to Editas Medicine’s First Quarter Conference Call. All participants are now in a listen-only mode.
12 Gene Editing Stocks With the Best Long-Term Potential
In this article, we will take a look at the 12 gene editing stocks with the best long-term potential.
Top 10 CRISPR Stocks To Buy
Molecular biology, genetics, and genomics are in a significant period in history where technical capabilities and methods enable the editing of specific DNA segments and base pairs in living organisms...
11 Most Promising Gene Editing Stocks According to Analysts
In this article, we will take a look at the 11 most promising gene editing stocks according to analysts.
Editas Medicine, Inc. (NASDAQ:EDIT) Q4 2022 Earnings Call Transcript
Operator: Good morning and welcome to Editas Medicine's Fourth Quarter and Full-year 2022 Conference Call. All participants are now in a listen-only mode.
5 Tech Stocks To Sell Now According to Cathie Wood
ARK Investment Management had been cutting its stake in Singapore-based tech company Sea Limited (NYSE:SE) since the first quarter of 2022.
10 Most Promising Gene Therapy Companies to Watch
Gene therapy is a revolutionary new technology that has followed the growing advances in computing power.
10 Best Gene Editing Stocks To Buy
A report by The Wall Street Journal dated September 16 suggests that Intellia Therapeutics, Inc.
Billionaire Hedge Funds
